Last €0.08 EUR
Change Today +0.003 / 3.85%
Volume 0.0
RV9C On Other Exchanges
Symbol
Exchange
Frankfurt
OTC US
As of 2:14 AM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

reva medical inc - cdi (RV9C) Snapshot

Open
€0.08
Previous Close
€0.08
Day High
€0.08
Day Low
€0.08
52 Week High
06/14/13 - €0.44
52 Week Low
04/15/14 - €0.08
Market Cap
27.1M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
334.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for REVA MEDICAL INC - CDI (RV9C)

Related News

No related news articles were found.

reva medical inc - cdi (RV9C) Related Businessweek News

No Related Businessweek News Found

reva medical inc - cdi (RV9C) Details

REVA Medical, Inc., a development stage medical device company, focuses on the development and commercialization of proprietary bioresorbable stent products. The company is developing and testing a bioresorbable stent to treat vascular disease in humans. Its products include ReZolve scaffold, a drug-eluting fully bioresorbable polymer stent to degrade and clear from the body. The company is also developing ReZolve2 scaffold, a drug-eluting fully bioresorbable polymer stent that is implanted using a balloon catheter to provide X-ray visibility, clinically relevant sizing, and a controlled and safe resorption rate. The company was formerly known as MD3, Inc. and changed its name to REVA Medical, Inc. in March 2002. REVA Medical, Inc. was founded in 1998 and is headquartered in San Diego, California.

81 Employees
Last Reported Date: 03/17/14
Founded in 1998

reva medical inc - cdi (RV9C) Top Compensated Officers

Co-founder, Chairman and Chief Executive Offi...
Total Annual Compensation: $359.7K
President and Chief Operating Officer
Total Annual Compensation: $340.8K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $275.2K
Senior Vice President of Clinical & Regulator...
Total Annual Compensation: $260.9K
Senior Vice President of Product Development
Total Annual Compensation: $254.0K
Compensation as of Fiscal Year 2013.

reva medical inc - cdi (RV9C) Key Developments

REVA Medical, Inc. - Special Call

To discuss the company's decision to fast-track the development of its 'thin-strut' fully bioresorbable scaffold family, Fantom(TM)

REVA Medical, Inc. to Focus on Breakthrough Scaffold: Fantom

REVA Medical, Inc. announced that it has positioned the company to fast-track the development of its "thin-strut" fully bioresorbable scaffold family, Fantom. The Fantom scaffold is made from a single piece of REVA's proprietary high performance desaminotyrosine polycarbonate polymer. Fantom is both less complex to manufacture and results in coronary scaffolds that are smaller and stronger than REVA's current ReZolve platform. Fantom is intended to halve the strut thickness of ReZolve without a decrease in radial strength. Thinner scaffold dimensions greatly improve deliverability and healing response, each of which can help to ensure broader adoption. Fantom maintains REVA's unique attributes of x-ray visibility and a single inflation to expand the device, features the Company believes competitive polymer scaffolds do not offer. Early bench tests and preclinical results of Fantom have demonstrated the substantial performance benefits of this product. The first human implants of the Fantom scaffold are planned to occur by the end of 2014, with commercialization targeted for mid-2016. As part of the plan to accelerate Fantom, REVA will cease expending further resources on ReZolve, other than to follow patients in the RESTORE CE Mark trial. Doing so allows the Company to focus all resources on preparing Fantom for human studies to begin by the end of this year. The Company has effected a significant reduction of personnel, eliminated ReZolve manufacturing overhead and reduced other costs not essential to the development and production of Fantom.

REVA Medical, Inc. Auditor Raises 'Going Concern' Doubt

REVA Medical, Inc. filed its 10-K on Mar 17, 2014 for the period ending Dec 31, 2013. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RV9C:GR €0.08 EUR +0.003

RV9C Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RV9C.
View Industry Companies
 

Industry Analysis

RV9C

Industry Average

Valuation RV9C Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REVA MEDICAL INC - CDI, please visit www.revamedical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.